Global Human Microbiome Sequencing Instrument Market Insights, Forecast to 2028

Market Analysis and Insights: Global Human Microbiome Sequencing Instrument Market
Due to the COVID-19 pandemic, the global Human Microbiome Sequencing Instrument market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period. Fully considering the economic change by this health crisis, Reagents and Kits accounting for % of the Human Microbiome Sequencing Instrument global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Research and Academic Institutions segment is altered to an % CAGR throughout this forecast period.
China Human Microbiome Sequencing Instrument market size is valued at US$ million in 2021, while the US and Europe Human Microbiome Sequencing Instrument are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Human Microbiome Sequencing Instrument landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.
The global key manufacturers of Human Microbiome Sequencing Instrument include Baseclear B.V., Beijing Genomics Institute (BGI) Genomics Co., Ltd, Charles River Laboratories International Inc., Clinical Microbiomics A/S, Eurofins Scientific SE, GENEWIZ, Inc., Illumina, Inc., Novogene Corporation and OraSure Technologies, Inc., etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Human Microbiome Sequencing Instrument Scope and Segment
Human Microbiome Sequencing Instrument market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Human Microbiome Sequencing Instrument market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Reagents and Kits
Instruments
Liquid Handling Instruments
Cytometers
Imaging Devices
Microplate Reader
Others
Segment by Application
Research and Academic Institutions
Pharmaceutical and Biotechnology Companies
Hospital and Clinic
Others
By Company
Baseclear B.V.
Beijing Genomics Institute (BGI) Genomics Co., Ltd
Charles River Laboratories International Inc.
Clinical Microbiomics A/S
Eurofins Scientific SE
GENEWIZ, Inc.
Illumina, Inc.
Novogene Corporation
OraSure Technologies, Inc.
Oxford Nanopore Technologies, Inc.
Pacific Biosciences of California, Inc.
QIAGEN N.V.
Second Genome, Inc.
Thermo Fisher Scientific Inc.
Viome, Inc.
CosmosID
Leucine Rich Bio Pvt. Ltd.
Microba
Microbiome Insights Inc.
Molzym GmbH & Co. KG
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE